Gene · 4919
ROR1: ROR family WNT receptor 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ROR1: ROR family WNT receptor 1. Genes, record 4919. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4919
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q01973 | Inactive tyrosine-protein kinase transmembrane receptor ROR1 | 937 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents160
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4777551 A1 | 2026-07-22 | 9 | Q01973 | Espacenet |
| EP 4772535 A1 | 2026-07-08 | 95 | Q01973 | Espacenet |
| JP 2026515434 A | 2026-05-18 | 72 | Q01973 | Espacenet |
| EP 4696329 A1 | 2026-02-18 | 87 | Q01973 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61152 | Q01973 | Espacenet |
| JP 2025538110 A | 2025-11-26 | 47 | Q01973 | Espacenet |
| KR 1020250163373 A | 2025-11-20 | 87 | Q01973 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8890 | Q01973 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9118 | Q01973 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 11535 | Q01973 | Espacenet |
1 to 10 of 160
See all 160 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| CIRMTUZUMAB | CHEMBL4297728 | Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor | INHIBITOR |
Source ChEMBL
Trials17
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06890884 | CIRMTUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT06717347 | CIRMTUZUMAB | PHASE3 | ClinicalTrials.gov | |
| NCT06395103 | CIRMTUZUMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05562830 | CIRMTUZUMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05458297 | CIRMTUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT05431179 | CIRMTUZUMAB | PHASE3 | ClinicalTrials.gov | |
| NCT05406401 | CIRMTUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT05156905 | CIRMTUZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT05144841 | CIRMTUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT05139017 | CIRMTUZUMAB | PHASE2/PHASE3 | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsNIH grants1,179
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ROR1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 31 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 26 | 2025 |
| R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 21 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 10 | 2025 |
| P30CA069533 | OHSU Knight Cancer Institute | 7 | 2025 |
| P01CA018029 | Adult Leukemia Research Center | 6 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 6 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 6 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 6 | 2025 |
| R01CA204484 | Novel Enediyne-Based Antibody-Drug Conjugates for Cancers | 6 | 2025 |
1 to 10 of 1,179Source NIH's project files
See all 1,179 nih grantsPapers2,258
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease. | Leukemia | 2026 | 42827116 | PubTator, text mining | PubMed |
| SLV-404, an anti-RYK antibody-drug conjugate, is effective in Richter transformation patient-derived xenografts. | Hemasphere | 2026 | 42824998 | PubTator, text mining | PubMed |
| ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma identifies a targetable vulnerability for ROR1-directed bispecific modalities. | Leukemia | 2026 | 42823506 | PubTator, text mining | PubMed |
| Multipronged enhancement of CART cell activity against ROR1 neoantigen by inhibition of H3K27 methyltransferase EZH2. | Cell Rep Med | 2026 | 42790422 | PubTator, text mining | PubMed |
| Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma. | Blood Neoplasia | 2026 | 42733493 | PubTator, text mining | PubMed |
| Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1. | MAbs | 2026 | 42731893 | PubTator, text mining | PubMed |
| Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates. | Leuk Lymphoma | 2026 | 42704791 | PubTator, text mining | PubMed |
Retraction notice to "Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer" [Int. J. Biol. Macromol. 221 (2022) 604-612]. | Int J Biol Macromol | 2026 | 42686485 | PubTator, text mining | PubMed |
| Comprehensive analysis of senescence-associated secretory phenotype-related signature for predicting prognosis and immunotherapy response in cervical cancer. | Comput Methods Biomech Biomed Engin | 2026 | 42643048 | PubTator, text mining | PubMed |
| Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer's Disease. | Neurotox Res | 2026 | 42635855 | PubTator, text mining | PubMed |
1 to 10 of 2,258
See all 2,258 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4919
GET https://conductscience.org/api/genes/v1/4919/patents?page=2